To include your compound in the COVID-19 Resource Center, submit it here.

Valeant's Pearson regrets drug pricing decisions

On Wednesday, Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) CEO Michael Pearson testified before the U.S.

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE